This site is intended for healthcare professionals
COMT inhibition in Parkinson’s Disease

Disease progression

Read time: 15 mins

PD progression is characterised by a worsening of motor and non-motor features, which can no longer be managed with symptomatic therapies1. Levodopa-induced motor complications are common due to increased disease severity and higher drug doses which cause a narrowing of the levodopa therapeutic window2.  

As PD advances complications related to long-term symptomatic treatment emerge, these include non-motor and motor fluctuations (Figure 1) as well as dyskinesia and psychosis1

Register free for full access to